Very low dose of flutamide in the treatment of hyperandrogenism

Gynecol Endocrinol. 2018 May;34(5):394-398. doi: 10.1080/09513590.2017.1397114. Epub 2017 Nov 6.

Abstract

Hyperandrogenism is a condition affecting 5-10% of adolescents. The aim of this study was to evaluate the efficacy of very low dose of flutamide in the treatment of hyperandrogenism in adolescence. One hundred and fifty-eight patients, presenting severe acne and/or hirsutism, received 62.5 mg/day of flutamide + ethinylestradiol + gestodene for 18 months. The patients were subjected to assessments of hepatic enzymes levels. Thirty subjects treated with drospirenone + ethinylestradiol represented the control group. After 18 months of treatment, it was obtained a decrease of hirsutism (-39.9%), an almost recovery of acne (98% of patients) with better results of those obtained in control group. Only one case of light hypertransaminasemia was recorded, regressed spontaneously. Very low dose of flutamide was successful and safe and in the treatment of hyperandrogenism in adolescence.

Keywords: Hirsutism; hormonal contraception; hyperandrogenism; flutamide.

MeSH terms

  • Acne Vulgaris / drug therapy*
  • Adolescent
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / therapeutic use*
  • Androstenes / administration & dosage
  • Androstenes / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Therapy, Combination
  • Ethinyl Estradiol / administration & dosage
  • Ethinyl Estradiol / therapeutic use
  • Female
  • Flutamide / administration & dosage
  • Flutamide / therapeutic use*
  • Hirsutism / drug therapy*
  • Humans
  • Hyperandrogenism / drug therapy*
  • Norpregnenes / administration & dosage
  • Norpregnenes / therapeutic use
  • Treatment Outcome
  • Young Adult

Substances

  • Androgen Antagonists
  • Androstenes
  • Norpregnenes
  • Gestodene
  • Ethinyl Estradiol
  • Flutamide
  • drospirenone